Rating Change
Wedbush analysts initiated coverage on Aktis Oncology, Inc. (NASDAQ:AKTS) with a rating of Outperform on August 19, 2026.
new coverageNASDAQ:AKTS
Wedbush Initiates Coverage on Aktis Oncology, Inc. (AKTS) with Outperform
Wedbush analysts initiated coverage on Aktis Oncology, Inc. (NASDAQ:AKTS) with a rating of Outperform on August 19, 2026.
At publication ·
What changed
Aktis Oncology, Inc. (NASDAQ:AKTS) · new coverage
- Firm
- Wedbush
- Rating
- Outperform
- Price at event
- $25.02
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Wedbush initiated coverage of Aktis Oncology (AKTS) with an Outperform rating on August 19, 2026, as the stock trades at $25.02 with a market capitalization of $1.1 billion.
Market Context
Aktis Oncology, Inc. operates in the Healthcare sector. The stock currently trades at $25.02 with a market capitalization of $1.1B. The stock has gained 20175.5% over the past 52 weeks.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Aktis Oncology, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Aktis Oncology, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | Wedbush | Outperform | N/A |
| Aug 19, 2026 | BMO Capital | Outperform | N/A |
| Jul 14, 2026 | JP Morgan | Overweight | N/A |
| Jun 16, 2026 | Raymond James | Strong Buy | N/A |
| Jun 02, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AKTS Stock Page
Frequently Asked Questions
What does the Outperform rating mean for AKTS?
A rating of Outperform from Wedbush reflects the analyst's outlook on Aktis Oncology, Inc. (NASDAQ:AKTS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AKTS forecast page.